Jardiance UTI Risk: Why It Happens and How to Reduce It

Jardiance (empagliflozin) raises UTI risk by forcing glucose into your urine, where it feeds bacteria and yeast that would otherwise have less to work with. The drug belongs to a class called SGLT2 inhibitors, which lower blood sugar by blocking the kidneys from reabsorbing glucose. That glucose ends up in the bladder, and the microbial consequences are real, though the size of the risk and who it affects most are more complicated than a simple yes-or-no warning suggests.

How Jardiance Changes the Urinary Environment

Your kidneys normally filter glucose out of the blood and then reclaim almost all of it before urine reaches the bladder. Jardiance blocks the transporter responsible for that reclamation. In a study of both healthy individuals and people with type 2 diabetes, empagliflozin reduced the kidney’s maximum capacity to reabsorb glucose by roughly 65 to 75 percent after two weeks, and it lowered the threshold at which glucose starts spilling into the urine to below 40 mg/dL, well under normal fasting blood sugar levels.¹ In practical terms, anyone taking Jardiance has measurable glucose in their urine around the clock, whether or not their blood sugar is well controlled. That constant presence of sugar creates conditions that matter to the microbes living in and around the urinary tract.

Why Sugar in Urine Promotes Infection

Glucose in urine does two things that work in bacteria’s favor. First, it speeds up bacterial growth. Research on E. coli, the bacterium behind most UTIs, has shown that adding glucose to urine enhances growth rates in both uropathogenic and non-uropathogenic strains.² Second, and perhaps more consequentially, glucose changes how those bacteria behave. When uropathogenic E. coli are exposed to the sugar-rich conditions that mimic a diabetic urinary tract, they ramp up biofilm formation, the slimy colonies that help bacteria stick to bladder walls and resist both the immune system and antibiotics.³ Gene expression analysis of these bacteria found broad changes in virulence and metabolic genes after just two hours of glucose exposure, suggesting the shift toward a more aggressive infection profile happens fast.

On top of what glucose does to bacteria, there is evidence that SGLT2 inhibitors may also dampen the body’s local defenses. Researchers have linked these drugs to reduced activity of neutrophils (the white blood cells that respond first to infections) and suppression of key inflammatory signals in the urinary tract.⁴ Inflammatory signaling through pathways like NF-κB may also be impaired, which could slow the body’s ability to clear bacteria once they take hold. Animal studies in diabetic rats treated with an SGLT2 inhibitor found elevated inflammatory markers in bladder and urethral tissue, pointing to ongoing immune activation that, paradoxically, does not seem to resolve the underlying vulnerability to infection.⁵

How Much the Risk Actually Increases

This is where the picture gets messier than the mechanism would predict. You would expect a clear, consistent increase in UTI rates across all the research, but the clinical evidence is genuinely mixed, depending on the study design and the comparison group.

Some real-world studies find a substantial bump. A Thai observational study of patients with type 2 diabetes found a UTI incidence of about 33 percent among SGLT2 inhibitor users, compared with roughly 12 percent among non-users, translating to nearly four times the risk.⁶ A large Indian study of over 15,000 patients similarly found that SGLT2 inhibitor users had higher urogenital infection rates than non-users, with the drug roughly tripling the odds.⁷ A Korean retrospective study found a significantly higher risk of both genital and urinary tract infections when SGLT2 inhibitors were added to metformin, compared with adding other diabetes drugs.⁸

But other well-designed studies reach a different conclusion. A large population-based Canadian study using propensity-score matching found no significant increase in UTI risk with SGLT2 inhibitors compared with several other diabetes drug classes, and actually found a lower risk compared with insulin.⁹ Another large study looking specifically at severe UTIs found the rate among SGLT2 inhibitor users was essentially identical to the rate among users of other diabetes drugs, and even slightly lower when compared with GLP-1 agonists.¹⁰ A population study of older adults with diabetes found the adjusted risk of UTI with SGLT2 inhibitors was not statistically different from that of another common diabetes drug class.¹¹

One proposed explanation for why the risk looks smaller in some studies: the increased urine flow that SGLT2 inhibitors cause through osmotic diuresis may partially offset the glucose problem by physically flushing bacteria out of the urinary tract before they can establish an infection.¹² You get more sugar in the urine, but you also produce more urine, and the flushing effect may counterbalance the bacterial growth advantage. This does not completely resolve the contradiction, but it helps explain why the clinical signal is weaker than the biology alone would predict.

Genital Fungal Infections Are the Clearer Signal

While the UTI evidence is mixed, the link between SGLT2 inhibitors and genital yeast infections is strong and consistent. The same population study that found no significant UTI increase did find a roughly 2.5-fold increase in genital mycotic (fungal) infections.¹¹ A review of heart failure trials likewise noted that SGLT2 inhibitors are consistently associated with more genital yeast infections, while the UTI signal has been inconsistent.¹³

When researchers look at the actual organisms behind UTIs in people taking SGLT2 inhibitors, E. coli remains the most common culprit, but fungal involvement appears more often than in non-users. A cross-sectional study found that Candida albicans was the identified pathogen in a number of UTI cases, with fungal infections more common among SGLT2 inhibitor users. Some patients had mixed bacterial and fungal infections simultaneously.¹⁴ Another study of patients with confirmed positive urine cultures found E. coli in over 80 percent of cases, with Klebsiella pneumoniae appearing as a secondary pathogen, sometimes alongside E. coli.¹⁵ The practical takeaway is that if you develop symptoms while taking Jardiance, your doctor may want to consider fungal infection alongside the usual bacterial suspects, particularly if standard antibiotics don’t clear things up.

Who Faces the Highest Risk

Not everyone on Jardiance has the same likelihood of developing a UTI. Several risk factors consistently emerge in the research:

Sex: Women are at higher risk than men, which mirrors UTI risk in the general population but is amplified by SGLT2 inhibitor use.
Age: Older adults, particularly those 65 and above, face higher rates.
Poor blood sugar control: People with HbA1c levels at 9 percent or higher have more infections, likely because they also have more glucose available to spill into urine.
Kidney function: Reduced kidney filtration and elevated urinary albumin levels both raise the risk.
Diabetic complications: People with existing microvascular complications from diabetes, such as nerve damage or retinal disease, are more vulnerable.
Mood disorders: Depression and related conditions were identified as independent risk factors, possibly through behavioral pathways like reduced self-care.

These risk factors were identified in a retrospective cohort study examining both first and recurrent infections in SGLT2 inhibitor users.¹⁶ The Thai observational study similarly confirmed that gender, age, and occupation were significant predictors.⁶ People with structural urinary tract abnormalities, catheter use, or a history of frequent UTIs represent another high-risk group, though studies often exclude these patients from analysis, which means the available data probably understates their risk.¹⁷

Rare but Serious Complications

Most UTIs on Jardiance are uncomplicated, meaning they affect the lower urinary tract and resolve with standard treatment. But regulatory agencies have flagged more serious outcomes. The FDA issued a label change for SGLT2 inhibitors in 2015 after receiving reports of pyelonephritis (kidney infection) and urosepsis (a bloodstream infection originating from the urinary tract).¹⁸ Case reports describe patients who progressed to septic shock within weeks of starting empagliflozin, even with previously well-controlled diabetes. These severe cases remain rare, but they underscore why any UTI symptoms on Jardiance warrant prompt medical attention rather than a wait-and-see approach.

An even rarer but alarming complication is Fournier gangrene, a rapidly spreading infection of the genital and perineal area that requires emergency surgery. The FDA identified 55 unique cases of Fournier gangrene in patients taking SGLT2 inhibitors over a six-year period, affecting both men and women, with onset ranging from as early as five days to nearly four years after starting the medication.¹⁹ Pharmacovigilance analysis of the FDA’s adverse event reporting database found that empagliflozin carries a particularly strong signal for Fournier gangrene compared to other drugs in the database.²⁰ To be clear, the absolute number of cases is very small relative to the millions of prescriptions written, but any unexplained pain, tenderness, or swelling in the genital area while on this drug should be treated as urgent.

Does Jardiance Carry More Risk Than Other SGLT2 Inhibitors

People sometimes ask whether switching from empagliflozin to dapagliflozin or canagliflozin would reduce their UTI risk. The evidence here is somewhat surprising. A large comparative effectiveness study found that canagliflozin was actually associated with a higher risk of severe UTIs than empagliflozin, while dapagliflozin showed no meaningful difference from empagliflozin for UTIs.²¹ For genital infections specifically, both canagliflozin and dapagliflozin had modestly lower rates than empagliflozin, though the differences were small. The Thai observational study found no meaningful difference in UTI incidence between empagliflozin and dapagliflozin users.⁶ In short, switching SGLT2 inhibitors is unlikely to solve the problem.

Practical Steps to Reduce Your Risk

You cannot eliminate the glucose in your urine while taking Jardiance, because that is how the drug works. But you can reduce the chance that the glucose leads to an actual infection.

Hydration is arguably the single most useful countermeasure. Since Jardiance already causes increased urination through osmotic diuresis, leaning into that by drinking plenty of water helps flush bacteria out of the urinary tract before they establish themselves. The same diuretic effect that the drug creates may partly explain why the clinical UTI risk is smaller than the lab biology would suggest.¹² Not fighting the increased urination with fluid restriction, and instead maintaining generous water intake, works with the drug’s mechanism rather than against it.

Genital hygiene matters more than it otherwise might. Because glucose-rich urine passes over the genital area, Candida and bacteria have a richer environment to colonize. Keeping the area clean and dry, wearing breathable underwear, and wiping front to back for women are standard recommendations, but they carry extra weight for SGLT2 inhibitor users. Patient education on hygiene and early symptom recognition has been specifically highlighted as a key strategy for reducing infection risk in this population.²²

Blood sugar control also plays a role beyond the drug’s direct effect. If your HbA1c is already high, even more glucose spills into the urine, amplifying the risk factor that Jardiance creates. Working to bring your overall blood sugar closer to target does not eliminate the drug-induced glycosuria, but it reduces the total glucose load in the urinary system.

Recognizing symptoms early is critical. Burning with urination, increased frequency, cloudy or strong-smelling urine, and pelvic discomfort are classic UTI signs. For genital yeast infections, watch for itching, redness, or unusual discharge. Getting prompt treatment for mild infections prevents them from progressing to the serious complications discussed earlier. Don’t wait to see if symptoms resolve on their own.

Should You Stop Jardiance After a UTI

This is one of the most consequential practical questions, and the evidence is surprisingly clear: for most people, the answer is no. A large recent study found that about a third of patients discontinued their SGLT2 inhibitor after experiencing a UTI.²³ Those who stopped the medication faced roughly 35 percent higher cardiovascular and kidney risks compared with those who continued, while the risk of recurrent UTI was no different between the two groups. In other words, quitting the drug did not protect against future UTIs but did cost people the heart and kidney benefits that Jardiance provides.

This does not mean you should ignore recurrent infections. If you are getting UTIs repeatedly, your doctor might investigate whether something else is contributing, adjust other medications, or in rare cases consider an alternative. But reflexively stopping Jardiance after a single uncomplicated UTI appears to do more harm than good. The Indian study also found an interesting wrinkle: combining an SGLT2 inhibitor with a DPP-4 inhibitor reduced the odds of infection compared with the SGLT2 inhibitor alone, suggesting that combination therapy choices can influence risk.⁷

When Studies Exclude the People Most at Risk

One limitation worth flagging: much of the reassuring clinical trial data comes from populations that excluded patients who would be most vulnerable. People with a prior history of UTI, catheter use, structural urinary abnormalities, severe kidney disease, or compromised immune systems are routinely excluded from SGLT2 inhibitor trials.¹⁷ If you fall into one of those categories, the studies saying “UTI risk isn’t significantly elevated” may not apply to you. The real-world observational studies that include a broader patient population tend to show higher UTI rates, which makes sense: you are seeing the drug used in bodies that are already more infection-prone. If you have a history of recurrent UTIs or any structural urinary issue, the conversation with your prescriber should be more cautious and individualized than the headline study findings might suggest.